Related references
Note: Only part of the references are listed.Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
Joshua Z. Press et al.
BMC CANCER (2008)
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance
Elizabeth M. Swisher et al.
CANCER RESEARCH (2008)
Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance
R. Salani et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2008)
A comprehensive modular map of molecular interactions in RB/E2F pathway
Laurence Calzone et al.
MOLECULAR SYSTEMS BIOLOGY (2008)
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Wataru Sakai et al.
NATURE (2008)
Resistance to therapy caused by intragenic deletion in BRCA2
Stacey L. Edwards et al.
NATURE (2008)
BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy
Jennifer E. Quinn et al.
CLINICAL CANCER RESEARCH (2007)
HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients
Marianne Tuefferd et al.
PLOS ONE (2007)
High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications
Kylie L. Gorringe et al.
CLINICAL CANCER RESEARCH (2007)
Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma
Anais Malpica et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2007)
Amplicon profiles in ovarian serous carcinomas
Kentaro Nakayama et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Evidence that p53-Mediated Cell-Cycle-Arrest Inhibits Chemotherapeutic Treatment of Ovarian Carcinomas
Carlos S. Moreno et al.
PLOS ONE (2007)
被撤回的出版物: An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer (Retracted article. See vol. 30, pg. 678, 2012)
Holly K. Dressman et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship
David W. Kindelberger et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2007)
Independent prognostic significance of cell cycle regulator proteins p16INK4a and pRb in advanced-stage ovarian carcinoma including optimally debulked patients:: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group
S. Kommoss et al.
BRITISH JOURNAL OF CANCER (2007)
Lessons from BRCA: The Tubal Fimbria Emerges as an Origin for Pelvic Serous Cancer
Christopher P. Crum et al.
CLINICAL MEDICINE & RESEARCH (2007)
Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways
Rong Wu et al.
CANCER CELL (2007)
Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma
Annette Staebler et al.
GENES CHROMOSOMES & CANCER (2006)
A mouse model for the molecular characterization of Brca1-associated ovarian carcinoma
Deyin Xing et al.
CANCER RESEARCH (2006)
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary
David M. Gershenson et al.
OBSTETRICS AND GYNECOLOGY (2006)
Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging
M. Takano et al.
BRITISH JOURNAL OF CANCER (2006)
Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas
LA Brown et al.
GYNECOLOGIC ONCOLOGY (2006)
The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome
F Medeiros et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2006)
HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays
D Mayr et al.
HISTOPATHOLOGY (2006)
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
T Bonome et al.
CANCER RESEARCH (2005)
Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein
Jane E. Armes et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2005)
The p53 pathway: positive and negative feedback loops
SL Harris et al.
ONCOGENE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Assessment of Her-1, Her-2, and Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma
CH Lee et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2005)
Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling
CB Gilks et al.
GYNECOLOGIC ONCOLOGY (2005)
Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential
I Meinhold-Heerlein et al.
ONCOGENE (2005)
Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis -: A mutational analysis with immunohistochemical correlation
G Singer et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2005)
Grading ovarian serous carcinoma using a two-tier system
A Malpica et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2004)
WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma
M Al-Hussaini et al.
HISTOPATHOLOGY (2004)
Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer
D Katsaros et al.
GYNECOLOGIC ONCOLOGY (2004)
Cancer genes and the pathways they control
B Vogelstein et al.
NATURE MEDICINE (2004)
Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer
A Bali et al.
CLINICAL CANCER RESEARCH (2004)
Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular Pathologic data
CB Gilks
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2004)
The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin
JD Seidman et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2004)
被撤回的出版物: The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study (Retracted Article. See vol 96, pg 1021, 2005)
EK Riener et al.
GYNECOLOGIC ONCOLOGY (2004)
Ovarian tumorigenesis - A proposed model based on morphological and molecular genetic analysis
IM Shih et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: A Gynecologic Oncology Group Study
L Havrilesky et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer
A du Bois et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Ovarian cancer: Strategies for overcoming resistance to chemotherapy
R Agarwal et al.
NATURE REVIEWS CANCER (2003)
Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group
MA Bookman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Distinct subtypes of serous ovarian carcinoma identified by p53 determination
H Lassus et al.
GYNECOLOGIC ONCOLOGY (2003)
Histopathologic features of genetically determined ovarian cancer
PA Shaw et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2002)
c-MYC: More than just a matter of life and death
S Pelengaris et al.
NATURE REVIEWS CANCER (2002)
Molecular mechanisms in signal transduction: New targets for the therapy of gynecologic malignancies
B Gabriel et al.
ONKOLOGIE (2002)
Current understanding of them epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer
SA Narod et al.
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2002)
Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential
MA Crispens et al.
OBSTETRICS AND GYNECOLOGY (2002)
Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences
A Tutt et al.
EMBO JOURNAL (2001)
Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation
B Modan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Ovarian surface epithelium: Biology, endocrinology, and pathology
N Auersperg et al.
ENDOCRINE REVIEWS (2001)
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer
HA Risch et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin
A Bhattacharyya et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Clinicopathologic features of BRCA-linked and sporadic ovarian cancer
J Boyd et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer
R Moslehi et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2000)
Loss of heterozygosity on chromosome 17q in epithelial ovarian tumors: Association with carcinomas with serous differentiation
A Garcia et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2000)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
Share Paper
